Multiscale Tumor Spatiokinetic Model for Intraperitoneal Therapy

This study established a multiscale computational model for intraperitoneal (IP) chemotherapy, to depict the time-dependent and spatial-dependent drug concentrations in peritoneal tumors as functions of drug properties (size, binding, diffusivity, permeability), transport mechanisms (diffusion, convection), spatial-dependent tumor heterogeneities (vessel density, cell density, pressure gradient), and physiological properties (peritoneal pressure, peritoneal fluid volume). Equations linked drug transport and clearance on three scales (tumor, IP cavity, whole organism). Paclitaxel was the test compound. The required model parameters (tumor diffusivity, tumor hydraulic conductivity, vessel permeability and surface area, microvascular hydrostatic pressure, drug association with cells) were obtained from literature reports, calculation, and/or experimental measurements. Drug concentration-time profiles in peritoneal fluid and plasma were the boundary conditions for tumor domain and blood vessels, respectively. The finite element method was used to numerically solve the nonlinear partial differential equations for fluid and solute transport. The resulting multiscale model accounted for intratumoral spatial heterogeneity, depicted diffusive and convective drug transport in tumor interstitium and across blood vessels, and provided drug flux and concentration as a function of time and spatial position in the tumor. Comparison of model-predicted tumor spatiokinetics with experimental results (autoradiographic data of 3H-paclitaxel in IP ovarian tumors in mice, 6 h posttreatment) showed good agreement (1% deviation for area under curve and 23% deviations for individual data points, which were several-fold lower compared to the experimental intertumor variations). The computational multiscale model provides a tool to quantify the effects of drug-, tumor-, and host-dependent variables on the concentrations and residence time of IP therapeutics in tumors.

[1]  Bin Chen,et al.  Predictive Models of Diffusive Nanoparticle Transport in 3-Dimensional Tumor Cell Spheroids , 2013, The AAPS Journal.

[2]  Jacek Waniewski,et al.  Computer simulations of osmotic ultrafiltration and small-solute transport in peritoneal dialysis: a spatially distributed approach. , 2012, American journal of physiology. Renal physiology.

[3]  Ze Lu,et al.  Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming. , 2011, Nanomedicine.

[4]  J. Au,et al.  Abstract 5453: Drug transport in peritoneal tumors during intraperitoneal therapy – evaluation by computational model , 2011 .

[5]  J. Au,et al.  Intraperitoneal therapy for peritoneal cancer. , 2010, Future oncology.

[6]  J. Au,et al.  Delivery of siRNA Therapeutics: Barriers and Carriers , 2010, The AAPS Journal.

[7]  Michael F. Flessner,et al.  Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence , 2010, Nature Reviews Clinical Oncology.

[8]  Beom Soo Shin,et al.  Use of an Anti-Vascular Endothelial Growth Factor Antibody in a Pharmacokinetic Strategy to Increase the Efficacy of Intraperitoneal Chemotherapy , 2009, Journal of Pharmacology and Experimental Therapeutics.

[9]  Ze Lu,et al.  Tumor-Penetrating Microparticles for Intraperitoneal Therapy of Ovarian Cancer , 2008, Journal of Pharmacology and Experimental Therapeutics.

[10]  D. Rockey,et al.  Effect of the nitric oxide donor V-PYRRO/NO on portal pressure and sinusoidal dynamics in normal and cirrhotic mice. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[11]  R. Jain,et al.  Cancer cell death enhances the penetration and efficacy of oncolytic herpes simplex virus in tumors. , 2008, Cancer research.

[12]  J. Au,et al.  Tumor Priming Enhances Delivery and Efficacy of Nanomedicines , 2007, Journal of Pharmacology and Experimental Therapeutics.

[13]  Ze Lu,et al.  Effects of Carrier on Disposition and Antitumor Activity of Intraperitoneal Paclitaxel , 2007, Pharmaceutical Research.

[14]  Ricky T. Tong,et al.  Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. , 2007, Cancer research.

[15]  Lalit Kumar,et al.  Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer , 2006, Indian Journal of Medical and Paediatric Oncology.

[16]  D-S Lee,et al.  Flow correlated percolation during vascular remodeling in growing tumors. , 2005, Physical review letters.

[17]  M. Flessner,et al.  The transport barrier in intraperitoneal therapy. , 2005, American journal of physiology. Renal physiology.

[18]  Hanna Parnas,et al.  Mathematical modeling and optimization of drug delivery from intratumorally injected microspheres. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[20]  W. Sessa,et al.  Antiangiogenic therapy: creating a unique "window" of opportunity. , 2004, Cancer cell.

[21]  Timothy W Secomb,et al.  A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. , 2004, Neoplasia.

[22]  Jessie L.-S. Au,et al.  Drug Delivery and Transport to Solid Tumors , 2003, Pharmaceutical Research.

[23]  I. Barasoain,et al.  Fast Kinetics of Taxol Binding to Microtubules , 2003, The Journal of Biological Chemistry.

[24]  B. Döme,et al.  Vascularization of cutaneous melanoma involves vessel co‐option and has clinical significance , 2002, The Journal of pathology.

[25]  Rakesh K Jain,et al.  Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. , 2002, The American journal of pathology.

[26]  E. Venkatraman,et al.  Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Wientjes,et al.  Clinical aspects of drug delivery to tumors. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[28]  E. Fishman,et al.  Tumor transport physiology: implications for imaging and imaging-guided therapy. , 2001, AJR. American journal of roentgenology.

[29]  E. Edelman,et al.  Carrier proteins determine local pharmacokinetics and arterial distribution of paclitaxel. , 2001, Journal of pharmaceutical sciences.

[30]  M. Wientjes,et al.  Kinetics of P-glycoprotein-mediated efflux of paclitaxel. , 2001, The Journal of pharmacology and experimental therapeutics.

[31]  Jessie L.-S. Au,et al.  Determinants of Paclitaxel Uptake, Accumulation and Retention in Solid Tumors , 2001, Investigational New Drugs.

[32]  B N Bundy,et al.  Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Verweij,et al.  Measurement of fraction unbound paclitaxel in human plasma. , 2000, Drug metabolism and disposition: the biological fate of chemicals.

[34]  M. Wientjes,et al.  Computational model of intracellular pharmacokinetics of paclitaxel. , 2000, The Journal of pharmacology and experimental therapeutics.

[35]  T. Edition,et al.  Formulary for Laboratory Animals , 1999 .

[36]  M. Wientjes,et al.  Determinants of paclitaxel penetration and accumulation in human solid tumor. , 1999, The Journal of pharmacology and experimental therapeutics.

[37]  J Verweij,et al.  Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications. , 1999, Cancer research.

[38]  B. Rippe,et al.  Clearance of Tracer Albumin from Peritoneal Cavity to Plasma at Low Intraperitoneal Volumes and Hydrostatic Pressures , 1998, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

[39]  M. Wientjes,et al.  Pharmacodynamics of immediate and delayed effects of paclitaxel: role of slow apoptosis and intracellular drug retention. , 1998, Cancer research.

[40]  M. Piver,et al.  Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer. , 1998, Gynecologic oncology.

[41]  W. Saltzman,et al.  Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. , 1998, Cancer research.

[42]  D. Alberts,et al.  Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. , 1996, The New England journal of medicine.

[43]  W. Mark Saltzman,et al.  Chemotherapeutic Drugs Released from Polymers: Distribution of 1,3-bis(2-chloroethyl)-l-nitrosourea in the Rat Brain , 1996, Pharmaceutical Research.

[44]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.

[45]  C. Nicholson Interaction between diffusion and Michaelis-Menten uptake of dopamine after iontophoresis in striatum. , 1995, Biophysical journal.

[46]  R K Jain,et al.  Diffusion and partitioning of proteins in charged agarose gels. , 1995, Biophysical journal.

[47]  M. Piver,et al.  Evaluation of survival after second‐line intraperitoneal cisplatin‐based chemotherapy for advanced ovarian cancer , 1994, Cancer.

[48]  K. Bhalla,et al.  Binding of taxol to human plasma, albumin and alpha 1-acid glycoprotein. , 1993, Research communications in chemical pathology and pharmacology.

[49]  R. Jain,et al.  Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma LS174T using dorsal chamber in SCID mice. , 1993, Microvascular research.

[50]  Maurie Markman Current status of intraperitoneal therapy for ovarian cancer , 1993, Current opinion in obstetrics & gynecology.

[51]  R. Barakat,et al.  Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  R K Jain,et al.  Determinants of tumor blood flow: a review. , 1988, Cancer research.

[53]  J. Levick Flow through interstitium and other fibrous matrices. , 1987, Quarterly journal of experimental physiology.

[54]  S. Howell,et al.  Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. , 1987, Cancer research.

[55]  M F Flessner,et al.  A distributed model of peritoneal-plasma transport: analysis of experimental data in the rat. , 1985, The American journal of physiology.

[56]  C. Nicholson,et al.  Ion diffusion modified by tortuosity and volume fraction in the extracellular microenvironment of the rat cerebellum. , 1981, The Journal of physiology.

[57]  V. Devita,et al.  Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. , 1980, Cancer research.

[58]  D. Collins,et al.  Peritoneal dialysis efficiency in relation to body weight , 1966 .

[59]  E. Reed,et al.  Steady-state plasma concentrations and effects of taxol for a 250 mg/m2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer , 2004, Cancer Chemotherapy and Pharmacology.

[60]  B. Rippe What is the role of albumin in proteinuric glomerulopathies? , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[61]  J. Au,et al.  Effect of dimethyl sulfoxide on bladder tissue penetration of intravesical paclitaxel. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  A. Verkman,et al.  Reduced osmotic water permeability of the peritoneal barrier in aquaporin-1 knockout mice. , 1999, The American journal of physiology.

[63]  David Odde Diffusion inside microtubules , 1998, European Biophysics Journal.

[64]  W. Deen Analysis Of Transport Phenomena , 1998 .

[65]  D. Song,et al.  Binding of taxol to plastic and glass containers and protein under in vitro conditions. , 1996, Journal of pharmaceutical sciences.

[66]  R K Jain,et al.  Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. , 1991 .

[67]  P. Sevelda,et al.  First experiences with intraperitoneal chemotherapy in ovarian cancer. , 1990, European journal of gynaecological oncology.

[68]  R K Jain,et al.  Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. , 1989, Microvascular research.